Pioneering research for rare diseases
Research and development
Complement alternative pathway activation is linked to several chronic orphan indications. Our strategy has been to select for drug candidates that selectively block the alternative pathway without blocking the classical pathway. Thus, our lead drug candidate humanized monoclonal antibodies do not block the classical pathway and are therefore selective for the alternative pathway.
We have generated the drug candidate humanized antibodies using a very tedious and complicated process. Each drug candidate has been crafted with care and selectivity using various technologies. The drug candidates bind the target protein of the alternative pathway with high affinity and selectivity. As a result, block the initiation and activation of the alternative pathway. The selected humanized monoclonal antibody blocks the formation of C3b and C3a via the alternative pathway. The formation of membrane attack complexes is also blocked by the antibody.
Our lead candidate neutralizes the protease complex of the alternative pathway. The drug neutralizes the existing and o be formed C3 and C5 convertases. two therapeutic candidates have now completed the safety evaluations and are waiting to be manufactured for the human phase I clinical trial.
While the selection of the drug is challenging and time consuming, we have selected a pipeline of neutralizing antibodies. While our lead drug candidates antibodies target the disease-associated portion of the immune system (alternative pathway) they do not affect the beneficial aspects of the immune system necessary for host defense (classical pathway).
NovelMed is currently seeking pharma/venture partners to develop its portfolio of unique therapies for orphan & non-orphan indications.
unique anti-inflamatory properties
Cytokines, activated pro-inflammatory cells, and tissue injury are all important in the disease pathogenesis. While some inflammatory markers may be important in acute indications, others may be more important for chronic diseases. For example, Vascular Endothelial Growth Factor (VEGF) is important for Age Related Macular Degeneration (AMD) as shown by the surging sales of Eylea® from Regeneron & Lucentis® from Genentech, Tumor Necrosis Factor (TNF) has been validated for the induction and progression of Rheumatoid Arthritis. Several anti-TNF humanized/fully human monoclonal antibodies are currently on the market with huge sales. Interleukins such as IL-1 beta is important for juvenile arthritis, and IL-6 for Uveitis (Xoma). These therapeutic advancements were based upon individually targeting VEGF, IL-1 or IL-6.
Our approach is to block the production of multiple inflammatory mediators with a single product (anti-complement antibody). We believe that blockade of multiple inflammatory mediators via a singular mechanism is the key to developing multiple-targeted therapies from a single site of action. Such a desirable approach makes us unique in the inflammatory space from the mechanistic standpoint.